Table 3.
Comparison of initial patient data grouped according to improvement or deterioration of clinical conditions
| Acute-phase examination | Patients who recovered (n = 24) |
Patients who deteriorated (n = 7) | Statistics |
|---|---|---|---|
| RR mean, mm Hg | 83 ± 13 | 84 ± 12 | NS |
| Body mass index | 28 ± 6 | 24 ± 4 | NS |
| Smoking, pack-years | 31 ± 13 | 57 ± 20 | NS |
| Diabetes, percentage | 14 | 33 | NS |
| Coronary artery disease, percentage | 29 | 100 | P < 0.05 |
| pH | 7.37 ± 0.06 | 7.33 ± 0.04 | P = 0.07 |
| Leukocytes, g/L | 11 ± 5 | 11 ± 5 | NS |
| Temperature,°C | 36.8 ± 0.6 | 36.3 ± 0.3 | P = 0.07 |
| ATS score | 3 ± 0.8 | 3 ± 0.8 | NS |
| PSI score | 101 ± 23 | 125 ± 13 | P < 0.05 |
| CURB-65 score | 1.6 ± 0.9 | 2.0 ± 0.6 | NS |
| APACHE II score | 13 ± 4 | 15 ± 2 | P = 0.06 |
| GCS score | 15 ± 0.3 | 14 ± 0.8 | P < 0.05 |
| ICDSC score | 3 ± 1 | 3 ± 1 | NS |
| ACE/AT inhibitors, percentage | 36 | 66 | NS |
| Calcium antagonists, percentage | 18 | 17 | NS |
| Beta-blocker, percentage | 32 | 66 | NS |
| Diuretics, percentage | 77 | 100 | NS |
| Statins, percentage | 14 | 33 | NS |
| Thrombo inhibitors, percentage | 32 | 66 | NS |
| Glucocorticoids, percentage | 41 | 33 | NS |
| β2 mimetics, percentage | 64 | 83 | NS |
| Theophylline, percentage | 23 | 17 | NS |
| EEG μV2 delta | 83 ± 74 | 68 ± 43 | NS |
| EEG μV2 theta | 60 ± 64 | 43 ± 41 | NS |
| EEG μV2 alpha | 122 ± 131 | 77 ± 65 | NS |
| EEG μV2 beta | 42 ± 27 | 29 ± 15 | NS |
| EEG percentage delta | 30 ± 16 | 31 ± 11 | NS |
| EEG percentage theta | 19 ± 12 | 19 ± 14 | NS |
| EEG percentage alpha | 35 ± 17 | 33 ± 17 | NS |
| EEG percentage beta | 16 ± 7 | 17 ± 9 | NS |
| EEG peak Hz delta | 1.2 ± 0.4 | 1.3 ± 0.3 | NS |
| EEG peak Hz theta | 6.6 ± 0.9 | 6.3 ± 1 | NS |
| EEG peak Hz alpha | 9.3 ± 0.9 | 9.7 ± 0.9 | NS |
| EEG peak Hz beta | 15 ± 2 | 16.4 ± 2.5 | NS |
| Visual evoked potential, μV | 7.4 ± 2.3 | 7.1 ± 2.8 | NS |
| Resting flow velocity, cm/second | 47 ± 14 | 48 ± 17 | NS |
| Gain, percentage | 15 ± 4 | 9 ± 3 | P < 0.05 |
| Natural frequency, 1/second | 0.21 ± 0.03 | 0.22 ± 0.08 | NS |
| Attenuation | 0.41 ± 0.19 | 0.31 ± 0.27 | NS |
| Rate time, seconds | 1.6 ± 1.3 | 0.9 ± 0.3 | NS |
Data are presented as mean ± standard deviation unless indicated otherwise. ACE, angiotensin-converting enzyme; APACHE II, Acute Physiology and Chronic Health Evaluation II; AT, angiotensin; ATS, American Thoracic Society Scale; CURB-65, confusion of new onset (defined as an abbreviated mental test score of 8 or less), urea of greater than 7 mmol/L (19 mg/dL), respiratory rate of 30 breaths per minute or greater, systolic blood pressure of less than 90 mm Hg or diastolic blood pressure of 60 mm Hg or less, and age of at least 65 years; EEG, electroencephalogram; GCS, Glasgow Coma Scale; ICDSC, Intensive Care Delirium Screening Checklist; NS, not significant; PSI, pneumonia severity index; RR, blood pressure.